Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232567 · ClinicalTrials.gov registry record · Phase 2
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
A Phase 2 study of Influenza, sponsored by Altimmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03232567 is a Phase 2 study of Influenza that has completed, run by Altimmune. The registered enrollment target is 60 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03232567, a Phase 2 study of Influenza, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).
Conditions Studied
Interventions
- BIOLOGICAL NasoVAX
Study Locations (1)
Maryland
- Optimal Health Research - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03232567
The ClinicalTrials.gov registry entry for NCT03232567 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which NasoVAX is the first listed.
NCT03232567 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03232567 about?
NCT03232567 is a clinical study titled "Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX". This is a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age. Subjects will be screened within 28 days of randomization (Day 1).
What is the current status of trial NCT03232567?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-09-18. Estimated completion is 2018-06-15.
What conditions does trial NCT03232567 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT03232567?
The interventions under investigation include: NasoVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT03232567?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03232567 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.